Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. More »

Featured News

Recent News

12/11/17GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
12/09/17GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
11/30/17Global Blood Therapeutics Announces New Employment Inducement Grants
11/13/17Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease

More »

Media Resources

Stay Informed

Sign up to receive email updates about ongoing sickle cell disease clinical studies, awareness and educational information and GBT news at:

Media Contact

Julie Normart